Wegovy 7.2mg UK: The New High-Dose Option (2026)

What is Wegovy 7.2mg?

Wegovy 7.2mg is the newest, higher-strength version of the popular weight loss medication Wegovy. It contains 7.2 milligrams of semaglutide, which is triple the standard dose of 2.4mg previously licensed for obesity treatment in the UK. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that works to reduce appetite and help people lose weight.

Wegovy 7.2mg was developed to improve weight loss results beyond what the 2.4mg dose offers. It is taken once weekly as a subcutaneous injection, under the skin, and is prescribed alongside lifestyle changes including diet and exercise. As with other doses of Wegovy, it requires a careful dose-escalation schedule to reduce side effects.

Why is Wegovy 7.2mg generating so much interest?

In early 2026, interest in Wegovy 7.2mg has surged dramatically in the UK, with online searches increasing by over 620%. This sharp rise reflects growing awareness of this new dose's potential to improve weight loss outcomes for people struggling with obesity or excess weight.

• People are increasingly looking for effective medical options to support weight management.
• Wegovy has a strong reputation due to solid clinical evidence supporting the 2.4mg dose.
• The new 7.2mg dose may represent a breakthrough for those who didn’t get sufficient results with lower doses or other treatments.
• Social media and health influencers have helped raise the profile of Wegovy 7.2mg in recent months.

Despite the hype, it’s important to remember that Wegovy 7.2mg is a prescription medication requiring assessment by your GP or specialist.

How does Wegovy 7.2mg differ from the standard Wegovy dose?

The main difference is the amount of semaglutide in each injection:

• Standard Wegovy dose: 2.4mg weekly, licensed in the UK since 2021 for adults with a BMI of 30 or over (or 27 with weight-related health conditions).
• Wegovy 7.2mg: A new, triple-strength dose of 7.2mg weekly, designed to maximise weight loss effects.

This higher dose has been demonstrated in clinical trials to produce greater average weight loss than 2.4mg. However, risks of side effects such as nausea, vomiting, and gastrointestinal discomfort may also increase, so monitoring by a healthcare professional is essential.

The injection method, dosing frequency (once weekly), and mechanism of action remain the same for both versions.

UK Availability and Pricing

As of mid-2026, Wegovy 7.2mg is available in the UK through private prescription only. It has not yet been approved or funded on the NHS, meaning most people will need to pay privately.

The typical price for a month's supply of Wegovy 7.2mg is around £269.99, depending on the pharmacy or private clinic. This is higher than the cost of the 2.4mg dose due to the increased drug content and novelty. Private weight management clinics and online UK pharmacies may supply it on prescription after an assessment.

The NHS currently offers lifestyle-based weight management support and may occasionally recommend GLP-1 drugs such as semaglutide, but the 7.2mg dose remains outside NHS standard provision. Make sure to discuss affordability and suitability with your GP as part of any treatment plan.

Clinical Evidence for Higher Doses

Recent clinical trials published in 2025 and early 2026 have evaluated semaglutide at doses up to 7.2mg for obesity treatment. Key findings include:

• Average weight loss of up to 20-25% of initial body weight over 68 weeks, significantly higher than the ~15% seen with 2.4mg.
• Improved metabolic markers such as blood sugar and cholesterol levels.
• Side effects consistent with lower doses but with increased frequency of gastrointestinal symptoms.
• Good tolerability when dose escalation is done carefully under medical supervision.

These promising results suggest the 7.2mg dose could benefit people who require more aggressive weight loss strategies, under close healthcare oversight.

Who Might Benefit from Wegovy 7.2mg?

Wegovy 7.2mg may be suitable for adults in the UK who:

• Have obesity (BMI of 30 or above) or overweight with related conditions (BMI 27+ with type 2 diabetes, hypertension, etc.)
• Have previously tried lower doses of semaglutide or other weight loss medications without sufficient results
• Are committed to combining medication with diet, exercise, and lifestyle changes
• Have no contraindications such as personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
• Understand the potential side effects and agree to regular GP or specialist follow-up

It is not suitable for pregnancy, breastfeeding, or people